FIELD: virology; biotechnology; immunology.
SUBSTANCE: invention concerns an immunobiological agent and a method of its use. The immunobiological agent was obtained on the basis of genetically modified human mesenchymal stem cells expressing the non-structural protein NS5A of the hepatitis C virus. The invention makes it possible to increase the cellular immune response, characterized by increased antigen-specific proliferation of lymphocytes, production of interferon-gamma and the formation of memory T cells.
EFFECT: invention can be used as one of the components of a specific preventive and therapeutic agent against a disease caused by the hepatitis C virus.
1 cl, 6 dwg, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOSTIMULATING COMBINATION FOR PREVENTION AND TREATMENT OF HEPATITIS C | 2006 |
|
RU2431499C2 |
| ANTI-HCV VACCINE | 2003 |
|
RU2323744C2 |
| METHOD FOR IMMUNE THERAPY OF CHRONIC VIRAL HEPATITIS C | 2016 |
|
RU2637631C2 |
| AGENTS AND METHODS BASED ON USING FIBRONECTIN OF DOMAIN EDA | 2006 |
|
RU2430738C2 |
| RECOMBINANT INFLUENZA VIRUS STRAIN A/PR8/HK-NS80E85A, EXPRESSING FRAGMENTS OF ESAT-6 AND AG85A MYCOBACTERIUM TUBERCULOSIS ANTIGENS, TO OBTAIN TUBERCULOSIS VECTORED VACCINE | 2018 |
|
RU2678175C1 |
| ARTIFICIAL GENE ENCODING THE BSI-COV-UB IMMUNOGEN PROTEIN, RECOMBINANT PLASMID DNA PBSI-COV-UB, WHICH ENSURES THE EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL POLYEPITOPE BSI-COV-UB IMMUNOGEN PROTEIN CONTAINING UBIQUITIN AND EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2-SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806590C1 |
| VACCINAL COMPOSITION AGAINST HEPATITIS C VIRUS | 2005 |
|
RU2351363C2 |
| RECOMBINANT INFLUENZA VIRUS A | 2001 |
|
RU2280690C2 |
| CHEMERICAL ANTIGENES FOR VACCINE AGAINST HEPATITIS C VIRUS | 2013 |
|
RU2639504C2 |
| ARTIFICIAL GENE ENCODING THE BSI-COV IMMUNOGEN PROTEIN, PBSI-COV RECOMBINANT PLASMID DNA PROVIDING EXPRESSION OF THE TARGET GENE, AND AN ARTIFICIAL BSI-COV POLYEPITOPE IMMUNOGEN PROTEIN CONTAINING EPITOPES OF SARS-CoV-2 VIRUS ANTIGENS AND INDUCING SARS-CoV-2- SPECIFIC T-CELL IMMUNITY | 2023 |
|
RU2806556C1 |
